Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Tweet Chat Recap with Dr. John Leonard, Lymphoma Program Director

On Wednesday, January 21st Lymphoma Program Director, Dr. John Leonard held his first Tweet Chat (#LeonardChat), answering questions about recent lymphoma related developments from the 2014 meetings of the American Society of Hematology.

In case you were unable to participate a transcript of the Tweet Chat is available.

Tweet Chat with Dr. John Leonard, Lymphoma Program Director

John Leonard, MD
John Leonard, MD

Please mark your calendars and join Dr. John Leonard, next Wednesday, January 21st from 4pm-5pm on Twitter for the inaugural #LeonardChat. The Lymphoma Program will be hosting a Tweet Chat, and Dr. Leonard will answer questions about the important abstracts and findings from the recent 2014 conference of the American Society of Hematology (ASH).

Dr. Leonard can be found on Twitter at: @JohnPLeonardMD while the Lymphoma Program can be found at: @lymphomaprogram

Location: Twitter
Date: Wednesday, January 21, 2014 4pm-5pm
Hashtag: #LeonardChat
Follow: @DrJohnPLeonardMD or @lymphomaprogram

Lenalidomide and Rituximab Combination Displays Promise for the Treatment of Patients with Mantle Cell Lymphoma

Investigators from around the world are taking notice of our results in treating patients with mantle cell lymphoma. (MCL) In the below video, Dr. Laurie Sehn from the University of British Columbia shares her thoughts on Dr. Jia Ruan’s clinical trial of lenalidomide plus rituximab for previously untreated mantle cell lymphoma.

 

 

In the following video Dr. Ruan further discusses results of her trial with lenalidomide and rituximab combination for patients with MCL.